Showing results (1-10 of 89) with videos related to
Sort By:
Pageof 9
Der Nervenarzt|February 7, 2018
[Coagulation factors and multiple sclerosis : Key factors in the pathogenesis?]K Göbel, C Kleinschnitz, S G MeuthDer Nervenarzt|June 8, 2011
[Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications]S Bittner, K Höhn, K Göbel, et al.Hamostaseologie|May 20, 2015
Platelets and vascular inflammation of the brainM Mezger, K Göbel, P Kraft, et al.Endocrine, Metabolic & Immune Disorders Drug Targets|March 10, 2007
Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006C Kleinschnitz, S G Meuth, B C Kieseier, et al.Der Nervenarzt|June 7, 2007
[Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis]C Kleinschnitz, S G Meuth, B C Kieseier, et al.Der Nervenarzt|November 18, 2008
[Multiple sclerosis -- a channelopathy? Targeting ion channels and transporters in inflammatory neurodegeneration]S G Meuth, N Melzer, C Kleinschnitz, et al.Journal of the Neurological Sciences|December 3, 2013
Long-term effects of dalfampridine in patients with multiple sclerosisT Ruck, S Bittner, O J Simon, et al.Clinical and Experimental Immunology|September 17, 2013
Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategiesN Melzer, S G MeuthDer Nervenarzt|March 30, 2016
[Actual medical care situation and therapeutic needs in multiple sclerosis: Impact of the Pharmaceutical Market Restructuring Act (AMNOG)]S Bittner, S G MeuthEuropean Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|September 22, 2019
Early effective treatment may protect from cognitive decline in paediatric multiple sclerosisA Johnen, C Elpers, E Riepl, et al.Pageof 9